Antengene Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jay Mei

Chief Executive Officer (CEO)

CN¥15.4m

Compensación total

Porcentaje del salario del CEO	38.7%
Permanencia del CEO	5.7yrs
Participación del CEO	26.2%
Permanencia media de la dirección	3.1yrs
Promedio de permanencia en la Junta Directiva	3.4yrs

Actualizaciones recientes de la dirección

Recent updates

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Jan 09

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

Sep 20

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

Apr 03

What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares?

Feb 22

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jay Mei en comparación con los beneficios de Antengene?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-CN¥581m
Sep 30 2023	n/a	n/a	-CN¥628m
Jun 30 2023	n/a	n/a	-CN¥676m
Mar 31 2023	n/a	n/a	-CN¥639m
Dec 31 2022	CN¥15m	CN¥6m	-CN¥601m
Sep 30 2022	n/a	n/a	-CN¥584m
Jun 30 2022	n/a	n/a	-CN¥567m
Mar 31 2022	n/a	n/a	-CN¥611m
Dec 31 2021	CN¥17m	CN¥5m	-CN¥656m

Compensación vs. Mercado: La compensación total de Jay($USD2.12M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD232.54K).

Compensación vs. Ingresos: La compensación de Jay ha sido consistente con los resultados de la empresa en el último año.

CEO

Jay Mei (58 yo)

5.7yrs

Permanencia

CN¥15,356,000

Compensación

Dr. Jay Mei, M.D. & Ph.D. is the Founder of Antengene Corporation and serves as Chairman & Chief Executive Officer at Antengene Corporation. Dr. Mei has experience in clinical research and development of o...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Mei	Founder	no data	CN¥15.36m	26.18% CN¥ 166.1m
Donald Andrew Lung	CFO & Executive Director	3.8yrs	CN¥8.87m	sin datos
Bo Shan	Chief Scientific Officer	3.1yrs	sin datos	sin datos
John F. Chin	Executive Director & Chief Business Officer	no data	CN¥5.93m	0.020% CN¥ 127.4k
Eitan Liu	Chief Operating Officer	no data	sin datos	sin datos
Kathryn Gregory	VP & Head of Corporate Business Development	2.9yrs	sin datos	sin datos
Shimin Sun	Corporate VP and Head of Clinical Enabling Functions & Operational Excellence	no data	sin datos	sin datos
Thomas Karalis	Corporate VP & Head of Asia Pacific Region	4yrs	sin datos	sin datos
Dirk Hoenemann	VP and Head of Medical Affairs for APAC & Early Clinical Development	3.8yrs	sin datos	sin datos
Xiaojing Zhang	Chief Medical Officer	1.3yrs	sin datos	sin datos
Yang Cao	Joint Company Secretary	no data	sin datos	sin datos
Wai Chiu Wong	Joint Company Secretary	2.1yrs	sin datos	sin datos

3.1yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6996 se considera experimentado (3.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Mei	Founder	5.7yrs	CN¥15.36m	26.18% CN¥ 166.1m
Donald Andrew Lung	CFO & Executive Director	2.8yrs	CN¥8.87m	sin datos
John F. Chin	Executive Director & Chief Business Officer	3.7yrs	CN¥5.93m	0.020% CN¥ 127.4k
Timothy M. Block	Member of Scientific Advisory Board	no data	sin datos	sin datos
Joseph Camardo	Member of Scientific Advisory Board	no data	sin datos	sin datos
Shaji K. Kumar	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jeffrey Barrett	Member of Scientific Advisory Board	no data	sin datos	sin datos
Robert Gale	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jing Qian	Independent Non-Executive Director	3.4yrs	sin datos	sin datos
Kan Chen	Non-Executive Director	3.1yrs	sin datos	sin datos
Sheng Tang	Independent Non-Executive Director	3.4yrs	sin datos	sin datos
Florence Houn	Member of the Scientific Advisory Board	no data	sin datos	sin datos

3.4yrs

Permanencia media

51yo

Promedio de edad

Junta con experiencia: La junta directiva de 6996 se considera experimentada (3.4 años de antigüedad promedio).

Antengene Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Antengene Corporation Limited Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

Antengene Corporation Limited Announces Management Changes

Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea

Recent updates

Consensus revenue estimates decrease by 63%, EPS upgraded

Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Consensus revenue estimates decrease by 24%, EPS upgraded

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance

Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States

Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

New minor risk - Shareholder dilution

Consensus revenue estimates decrease by 16%, EPS upgraded

First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022)

Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023

Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

New minor risk - Share price stability

Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma

Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate

Antengene Corporation Limited Announces Executive Changes

Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer

Less than half of directors are independent

Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037

Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma

First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021)

Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022

We Think Antengene (HKG:6996) Can Afford To Drive Business Growth

Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018

Less than half of directors are independent

Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

Antengene Corporation Limited Announces Management Changes

Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037

Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors

Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial

National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China

Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

Antengene Announces The Approval by Human Research Ethics Committeein Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma

Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)

Non-Executive Director Zhen Li has left the company

Non-Executive Director Zhen Li has left the company

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

Antengene Corporation Limited Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome

Antengene Corporation Limited Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial

Antengene Corporation Limited Receives the Approval of the Investigational New Drug Application by the National Medical Products Administration

Antengene Corporation Limited Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies